This page shows the latest Janet Woodcock news and features for those working in and with pharma, biotech and healthcare.
These approvals mark the first generic approvals of a direct oral anticoagulant,” said Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research (CDER). ... Unlike older anticoagulants like warfarin, “direct oral
This decline isn’t worrying markets, the industry or regulators unduly, however, with FDA stalwart Janet Woodcock promising that the agency will maintain the reforming programme established by the energetic and
Janet Woodcock. Responding to these trends on Tuesday was one of the agency’s longest serving and most senior officials, Janet Woodcock, director of the FDA’s Center for Drug Evaluation ... A detailed note from SVB seen by FiercePharma reported that
In a statement, the director of the FDA’s Center for Drug Evaluation and Research (CDER) – Janet Woodcock (pictured below) – said the approval “is part of our longstanding commitment to advance
that the firm was emboldened by the FDA’s approval last year of another DMD therapy from Sarepta - Exondys 51 (eteplirsen) - after Janet Woodcock, head of the agency’s Center for
The abuse and manipulation of reformulated Opana ER by injection has resulted in a serious disease outbreak,” said Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research.
More from news
Approximately 1 fully matching, plus 34 partially matching documents found.
That idea is now mainstream. “It turns out that what is really bothering the patient and what is really bothering the doctor can be radically different things,” Janet Woodcock, director of ... Woodcock’s views and the research that shaped them have
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...